High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive Non-Hodgkin Lymphoma (NHL) in adults.

High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive Non-Hodgkin Lymphoma (NHL) in adults. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive Non-Hodgkin Lymphoma (NHL) in adults. Abstract Text:

A Greb,J Bohlius,D Schiefer,G Schwarzer,H Schulz,A Engert,

BACKGROUND: High-dose chemotherapy with autologous stem cell support (HDT) has been proven effective in relapsed aggressive non-Hodgkin lymphoma (NHL). However, conflicting results of HDT as part of first-line treatment have been reported in randomised controlled trials (RCTs). We undertook a systematic review and meta-analysis to assess the effects of such treatment. OBJECTIVES: To determine whether high-dose chemotherapy with autologous stem cell transplantation as part of first-line treatment improves survival in patients with aggressive non-Hodgkin lymphoma. SEARCH STRATEGY: MEDLINE, EMBASE, Cancer Lit, the Cochrane Library and smaller databases, Internet-databases of ongoing trials, conference proceedings of the American Society of Clinical Oncology and the American Society of Hematology were searched. We included full-text, abstract publications and unpublished data. SELECTION CRITERIA: Randomised controlled trials comparing conventional chemotherapy versus high-dose chemotherapy in the first-line treatment of adults with aggressive non-Hodgkin lymphoma were included in this review. DATA COLLECTION AND ANALYSIS: Eligibility and quality assessment, data extraction and analysis were done in duplicate. All authors were contacted to obtain missing data and asked to provide individual patient data. MAIN RESULTS: Fifteen RCTs including 3079 patients were eligible for this meta-analysis. Overall treatment-related mortality was 6.0% in the HDT group and not significantly different compared to conventional chemotherapy (OR 1.33 [95% CI 0.91 to 1.93], P=0.14). 13 studies including 2018 patients showed significantly higher CR rates in the group receiving HDT (OR 1.32, [95% CI 1.09 to 1.59], P=0.004). However, HDT did not have an effect on OS, when compared to conventional chemotherapy. The pooled HR was 1.04 ([95% CI 0.91 to 1.18], P=0.58). There was no statistical heterogeneity among the trials. Sensitivity analyses underlined the robustness of these results. Subgroup analysis of prognostic groups according to IPI did not show any survival difference between HDT and controls in 12 trials (low and low-intermediate risk IPI: HR 1.41[95% CI 0.95 to 2.10], P=0.09; high-intermediate and high risk IPI: HR 0.97 [95% CI 0.83 to 1.13], P=0.71. Event-free survival (EFS) also showed no significant difference between HDT and CT (HR 0.93, [95% CI 0.81 to 1.07], P=0.31). Other possible risk factors such as the proportion of patient with diffuse large cell lymphoma, protocol adherence, HDT strategy, response status before HDT, conditioning regimens and methodological issues were analysed in sensitivity analyses. However, there was no evidence for an association between these factors and the results of our analyses. AUTHORS' CONCLUSIONS: .Despite higher CR rates, there is no benefit for high-dose chemotherapy with stem cell transplantation as a first line treatment in patients with aggressive NHL.

High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive Non-Hodgkin Lymphoma (NHL) in adults. Publishing Authors By Initials

A Greb,J Bohlius,D Schiefer,G Schwarzer,H Schulz,A Engert,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive Non-Hodgkin Lymphoma (NHL) in adults. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Cochrane database of systematic reviews (Online)

VOLUME:

Page Numbers: CD004024

Journal Abbreviation:

ISSN: 1469-493X

DAY: 23

MONTH: 01

YEAR: 2008

High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive Non-Hodgkin Lymphoma (NHL) in adults. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 100909747

High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive Non-Hodgkin Lymphoma (NHL) in adults. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive Non-Hodgkin Lymphoma (NHL) in adults. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive Non-Hodgkin Lymphoma (NHL) in adults.

AFFILIATION:

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Cochrane Database Syst Rev

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive Non-Hodgkin Lymphoma NHL in adults Related Publications

• Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials.
• Biology, clinical course and management of nodular lymphocyte-predominant hodgkin lymphoma.
• Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma.
• Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG).
• Control of visually guided behavior by distinct populations of spinal projection neurons.
• Current treatment strategies of the German Hodgkin Study Group (GHSG).
• Differences in hematotoxicity between male and female patients with Hodgkin lymphoma and other malignancies.
• Eighth biannual report of the Cochrane Haematological Malignancies Group--focus on chronic lymphatic leukemia.
• Escape behavior elicited by single, channelrhodopsin-2-evoked spikes in zebrafish somatosensory neurons.
• Familial combined hyperlipidaemia: how can genetic disorders be common, complex and comprehensible?
• Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG).
• Genetic Variants of FTO Influence Adiposity, Insulin Sensitivity, Leptin Levels, and Resting Metabolic Rate in the Quebec Family Study.
• Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma.
• High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive Non-Hodgkin Lymphoma (NHL) in adults.
• Hodgkin's disease. Future treatment strategies: fact or fiction?
• Human Leukocyte Antigen-B-Associated Transcript 3 Is Released from Tumor Cells and Engages the NKp30 Receptor on Natural Killer Cells.
• Immunotherapy of Hodgkin's lymphoma.
• K45R variant of squalene synthase increases total cholesterol levels in two study samples from a French Canadian population.
• Lymphocyte-predominant and classical Hodgkin's lymphoma--comparison of outcomes.
• Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group.
• Non-Hodgkin's Lymphoma: A Review of Immunotherapeutic Approaches to Treatment.
• Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin's Lymphoma.
• [Antibiotic therapy of endocarditis lenta.]
• [Effect of intraoperative blood loss on the function of natural killer cells in tumors of the upper gastrointestinal tract]
• [Thoracic surgery emergencies in early childhood]